Professor Kevin Grimes, Co-Director of SPARC at Stanford University and Vice President of SPARC Global USA, has stated that Nigeria possesses a distinct opportunity to convert scientific discoveries into practical healthcare solutions. This statement was made during the SPARC Africa Translational Research Boot Camp and Scientific Conference taking place in Abuja this week.
In a discussion with ARISE News on Monday, Grimes explained that this initiative is a partnership between the National Institute for Pharmaceutical Research and Development (NIPRD) and Stanford University’s SPARC programme, which aims to bridge the essential gap between laboratory innovations and the treatments accessible to patients.
He pointed out, "The core issue is that academics receive recognition for basic research, but there is a missing link in transitioning those discoveries to patients suffering from unmet medical needs. We refer to this disconnect as the ‘valley of death.’"
Moreover, Grimes mentioned that in addition to funding challenges, the lack of expertise in mitigating project risks discourages companies and venture capitalists from investing in early-stage biomedical ventures.
He underscored that while the SPARC model has proven successful worldwide, it needs to be tailored to the unique structural conditions of Africa. “In the US, only a minority of universities have the capacity to achieve this, and the situation varies globally. With appropriate leadership, political commitment, and funding, academics can be trained to make these initiatives successful.”
The boot camp, which runs throughout the week in Abuja, includes practical training sessions from 8 a.m. to 6 p.m., featuring seminars, lectures, and breakout workshops. Participants consist of African scientists, university administrators, industry officials, and heads of teaching hospitals.
Grimes further highlighted that the mentorship provided by SPARC continues beyond project kick-off to include financing and commercialization, ensuring comprehensive support past the conference.
"We maintain mentorship from the very beginning until the projects secure full funding and progress. That is the most vital aspect,” he reiterated.
Addressing the importance of ownership in innovations, Grimes stated, “The objective is for African researchers to create therapies and diagnostics that tackle local challenges. Ownership should rest with African institutions, which will hold patents, license them, and gain from royalties, preferably keeping enterprises and innovations within Africa.”
He also remarked on significant challenges facing Nigerian researchers, identifying two primary obstacles: obtaining funding to mitigate project risks and persuading investors that these innovations will benefit patients and deliver returns.
"Therapeutics developed in Nigeria could address the needs of populations of African descent worldwide, generating revenues that flow back to local researchers and institutions,” Grimes noted.
He concluded that the long-term effects of SPARC Nigeria will be evident through patents, spin-off enterprises, startups, and clinical trials within a timeframe of 18 to 24 months.
He further emphasized the necessity of aligning the final product from the outset, ensuring each innovation effectively addresses genuine health challenges and is incorporated into a sustainable ecosystem.
Comments (0)
You must be logged in to comment.
Be the first to comment on this article!